Citigroup
KBIO

Citigroup’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

Citigroup’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-498
Closed -$1K – 8351
2015
Q3 		$1K Buy
498
+155
+45% +$409 ﹤0.01% 7330
2015
Q2 		$1K Buy
+343
New +$1.45K ﹤0.01% 7480
2015
Q1 		– Sell
-61
Closed -$1K – 7865
2014
Q4 		$1K Buy
+61
New +$871 ﹤0.01% 7076
2014
Q3 		– Sell
-161
Closed -$3K – 7677
2014
Q2 		$3K Sell
161
-69
-30% -$1.18K ﹤0.01% 6714
2014
Q1 		$5K Sell
230
-341
-60% -$9.88K ﹤0.01% 6629
2013
Q4 		$20K Buy
571
+486
+572% +$16.3K ﹤0.01% 6190
2013
Q3 		$3K Buy
85
+84
+8,400% +$3.83K ﹤0.01% 6571
2013
Q2 		$0 Buy
+1
New +$45 ﹤0.01% 6910

Other funds holding KBIO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Citigroup's KBIO Position: Q4 2015 in Review

Citigroup sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q4 2015, closing a stake of 498 shares — an estimated $1K sold.

Citigroup first reported a position in KBIO in Q2 2013 and held it in 8 quarters. The position peaked at $20K in Q4 2013. 17 funds tracked by Wall St. Rank hold KBIO as of Q4 2015.

  • Citigroup reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q4 2015 after selling out during the quarter.
  • Citigroup sold 498 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q4 2015, an estimated $1K.
  • Citigroup first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q2 2013 and held it in 8 quarters.
  • Citigroup's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $20K in Q4 2013.
  • 17 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q4 2015.

Based on Citigroup's 13F filing for Q4 2015, filed 12 Feb 2016.